Join the club for FREE to access the whole archive and other member benefits.

Clene's neurotherapeutics using metals enter human trials

Novel approach with gold nanocatalyst technology to reverse neurodegenerative disease

05-Jan-2021

Key points from article :

Clene Nanomedicine developed a new class of neuro-therapeutics called nanocatalysts.

Completed a $42 million Series D financing last summer.

"Oral, water-based nanotherapeutic based on metals may have disease treating benefits.” - Rob Etherington, CEO of Clene Nanomedicine.

Using clean-surfaced metallic nanocrystals to target conditions is completely unique.

“Make highly faceted, clean-surfaced gold nanocrystals and use them in pharmaceutical applications,” - Etherington.

Bioenergetic gold-based nanocatalyst accelerate neurorepair for patients with neurodegenerative disease.

Concluded all of the safety and toxicity work, and is now in a number of clinical studies.

"We can potentially reverse amyotrophic lateral sclerosis, multiple sclerosis (MS) and Parkinson’s disease,” - Etherington.

Phase 2 trials for both MS and Parkinson’s designed to prove that CNM-Au8 is driving biological energetic reactions.

“The goal is to build a Phase 3 study to evaluate the investigational products.” - Etherington.

Mentioned in this article:

Click on resource name for more details.

Clene Nanomedicine

Biopharmaceutical company based in Salt Lake City, Utah

Rob Etherington

President and Chief Executive officer at Clene Nanomedicine

Topics mentioned on this page:
Parkinson’s Disease, Musculoskeletal